Liver investigation: testing marker utility in steatohepatitis

  • Description
  • Details
  • Subprojects
  • History
  • Publications
  • Patents
  • Trials
Project Title: Liver investigation: testing marker utility in steatohepatitis
Project Number: CORDIS-212225
Project web address: Follow on CORDIS
 
Project Description:
Strongly associated with the epidemics of obesity and type 2 diabetes that are testing healthcare systems worldwide, Non-Alcoholic Fatty Liver Disease (NAFLD) is an increasingly common cause of advanced liver disease that is characterized by substantial inter-patient variability in severity and rate of progression. It is currently assessed by liver biopsy, an invasive, costly and risky procedure. The lack of noninvasive biomarkers has hampered patient care and impeded drug development by complicating conduct of clinical trials.The overarching aim of LITMUS is to develop, robustly validate and advance towards regulatory qualification biomarkers that diagnose, risk stratify and/or monitor NAFLD/NASH progression and fibrosis stage. This will be achieved through a goal-oriented, tri-partite collaboration delivering a definitive and impartial evaluation platform for biomarkers, bringing together: (i) End-users of biomarker technologies (clinicians with expertise in NAFLD and the pharmaceutical industry)? (ii) Independent academics with expertise in the evaluation of medical test/biomarker performance? and (iii) Biomarker researchers and developers (academic or commercial). LITMUS has the demonstrable capability to fulfil the IMI call remit. Built upon foundations laid by the EU-funded FLIP/EPoS projects and long-established, successful scientific collaborations amongst many of Europe’s leading clinical-academic centres, LITMUS is at a unique advantage due to its existing large-scale patient cohorts, bioresources and multi-omics datasets. Consortium members are internationally recognised experts with substantial relevant expertise supporting the program’s clear focus on biomarker identification, validation and accelerating EMA/FDA qualification. Thus, LITMUS is powered to provide clarity on biomarker validity for NAFLD at scale and pace: supporting drug development and the targeting of medical care and limited healthcare resources to those at greatest need.
 
Project Terms:
topic corda proteomics clinical medicine cohort studies transcriptomics gastroenterology and hepatology glycomics metabolomics
Project Title: Liver investigation: testing marker utility in steatohepatitis
Project Number: CORDIS-212225
Project web address: Follow on CORDIS
Organization: University Of Newcastle Upon Tyne, United Kingdom, Newcastle Upon Tyne
Collaborators: University Of Birmingham, GB
University Of Nottingham, GB
Somalogic, Inc., US
University Of Bern, CH
Università Cattolica Del Sacro Cuore, IT
Università Degli Studi Di Milano, IT
Università Degli Studi Di Torino, IT
The Chancellor, Masters And Scholars Of The University Of Oxford, GB
The Chancellor, Masters And Scholars Of The University Of Cambridge, GB
Università Degli Studi Di Palermo, IT
Université D'Angers, FR
Novo-Nordisk A/S, DK
Helsingin Yliopisto, FI
Pfizer Ltd, GB
Servicio Andaluz De Salud, ES
Assistance Publique - Hopitaux De Paris, FR
Eli Lilly Company Limited, GB
Novartis Pharma Ag, CH
Universitair Medisch Centrum Utrecht, NL
Universitaetsklinikum Aachen, DE
Orebro University, SE
Sanofi-Aventis Deutschland Gmbh, DE
Medizinische Universitaet Wien, AT
Universitaetsmedizin Der Johannes Gutenberg-Universitaet Mainz, DE
Asociación Centro De Investigación Cooperativa En Biociencias, ES
Genfit, FR
Ixscient Limited, GB
Ethniko Kai Kapodistriako Panepistimio Athinon, GR
Boehringer Ingelheim International Gmbh, DE
Luxembourg Institute Of Health, LU
Universitaetsklinikum Wuerzburg - Klinikum Der Bayerischen Julius-Maximilians-Universitat, DE
Takeda Development Centre Europe Ltd., GB
Universitair Ziekenhuis Antwerpen, BE
Faculdade De Medicina Da Universidade De Lisboa, PT
Perspectum Diagnostics Ltd, GB
Faculdade De Farmácia Da Universidade De Lisboa, PT
Academisch Medisch Centrum Bij De Universiteit Van Amsterdam, NL
Linkopings Universitet, SE
One Way Liver Sl, ES
Exalenz Bioscience Ltd, IL
Inst Cardiometabolisme Nutrition Ican, FR
Antaros Medical Ab, SE
European Association For The Studyof The Liver, CH
Intercept Pharma Europe Ltd, GB
Ellegaard Gottingen Minipigs As, DK
Nordic Bioscience Compound Development A/S, DK
 
Project Categories:
Natural Sciences > Aging-related markers and targets > Biomarkers of diseases
 
Other Information:
Fiscal Year: 2017
Project Start Date: 1 November 2017
Project End Date: 31 October 2022
Project program: H2020-EU.3.1.7.13.
 
Project Funding Information:
Year Funding Organization Total Funding, $
2017 European Research Council $39,291,609
Project Title: Liver investigation: testing marker utility in steatohepatitis
Project Number: CORDIS-212225
Project web address: Follow on CORDIS
 
Title FY Funding
There are no results for this project in database.
Project Title: Liver investigation: testing marker utility in steatohepatitis
Project Number: CORDIS-212225
Project web address: Follow on CORDIS
 
Project Title Organization FY Funding
Project Title: Liver investigation: testing marker utility in steatohepatitis
Project Number: CORDIS-212225
Project web address: Follow on CORDIS
 
Title Journal Year Country Rel
Project Title: Liver investigation: testing marker utility in steatohepatitis
Project Number: CORDIS-212225
Project web address: Follow on CORDIS
 
Title Year
Project Title: Liver investigation: testing marker utility in steatohepatitis
Project Number: CORDIS-212225
Project web address: Follow on CORDIS
 
Title Phase Year